CHEK2 I157T associates with familial and sporadic colorectal cancer

被引:67
作者
Kilpivaara, O.
Alhopuro, P.
Vahteristo, P.
Aaltonen, L. A.
Nevanlinna, H.
机构
[1] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Dept Med Genet, Helsinki, Finland
关键词
D O I
10.1136/jmg.2005.038331
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Recently, a functionally defective CHEK2 variant I157T has been proposed to associate with an increased risk of several types of cancer. We investigated the CHEK2 I157T variant for colorectal cancer (CRC) predisposition in a large population based study including a significant number of familial CRC cases. Methods: We screened the CHEK2 I157T variant in a population based series of 1042 Finnish CRC patients using restriction fragment length polymorphism. Mutation status was studied for correlation with clinical characteristics and family history of CRC and other cancers. Results: The frequency of CHEK2I157T was significantly higher in CRC patients (7.8%, 76/972) than in healthy population controls (5.3%, 100/1885) (OR = 1.5, 95% CI 1.1 to 2.1, p = 0.008). The significant association of CHEK2 I157T with CRC was observed among patients with ( 10.4%, 14/135) and without (7.4%, 62/837) a family history of CRC (OR = 2.1, 95% CI 1.1 to 3.7, p = 0.01; OR= 1.4, 95% CI 1.0 to 2.0, p = 0.03; respectively). A trend towards higher variant frequency was also noted among patients with multiple primary tumours and a family history of any cancer. Conclusions: CHEK2 I157T associates with an increased risk of CRC: the association was observed both among familial and sporadic CRC patients. Furthermore, the higher frequency of I157T among patients with multiple primary tumours as well as those with a family history of any cancer supports a role for CHEK2 I157T as a susceptibility allele for multiple cancer types.
引用
收藏
页数:4
相关论文
共 23 条
  • [1] Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
    Aaltonen, LA
    Salovaara, R
    Kristo, P
    Canzian, F
    Hemminki, A
    Peltomäki, P
    Chadwick, RB
    Kääriäinen, H
    Eskelinen, M
    Järvinen, H
    Mecklin, JP
    de la Chapelle, A
    Percesepe, A
    Ahtola, H
    Härkönen, N
    Julkunen, R
    Kangas, E
    Ojala, S
    Tulikoura, J
    ValKamo, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) : 1481 - 1487
  • [2] Chk1 and Chk2 kinases in checkpoint control and cancer
    Bartek, J
    Lukas, J
    [J]. CANCER CELL, 2003, 3 (05) : 421 - 429
  • [3] Association of two mutations in the CHEK2 gene with breast cancer
    Bogdanova, N
    Enssen-Dubrowinskaja, N
    Feshchenko, S
    Lazjuk, GI
    Rogov, YI
    Dammann, O
    Bremer, M
    Karstens, JH
    Sohn, C
    Dörk, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) : 263 - 266
  • [4] The mismatch repair system is required for S-phase checkpoint activation
    Brown, KD
    Rathi, A
    Kamath, R
    Beardsley, DI
    Zhan, QM
    Mannino, JL
    Baskaran, R
    [J]. NATURE GENETICS, 2003, 33 (01) : 80 - 84
  • [5] CHEK2 is a multiorgan cancer susceptibility gene
    Cybulski, C
    Górski, B
    Huzarski, T
    Masojc, B
    Mierzejewski, M
    Debniak, T
    Teodorczyk, U
    Byrski, T
    Gronwald, J
    Matyjasik, J
    Zlowocka, E
    Lenner, M
    Grabowska, E
    Nej, K
    Castaneda, J
    Medrek, K
    Szymanska, A
    Szymanska, J
    Kurzawski, G
    Suchy, J
    Oszurek, O
    Witek, A
    Narod, SA
    Lubinski, J
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (06) : 1131 - 1135
  • [6] Novel founder CHEK2 mutation is associated with increased prostate cancer risk
    Cybulski, C
    Huzarski, T
    Górski, B
    Masojc, B
    Mierzejewski, M
    Debniak, T
    Gliniewicz, B
    Matyjasik, J
    Zlowocka, E
    Kurzawski, G
    Sikorski, A
    Posmyk, M
    Szwiec, M
    Czajka, R
    Narod, SA
    Lubinski, J
    [J]. CANCER RESEARCH, 2004, 64 (08) : 2677 - 2679
  • [7] Colorectal cancer and the CHEK2 1100delC mutation
    de Jong, MM
    Nolte, IM
    Meerman, GJT
    van der Graaf, WTA
    Mulder, MJ
    van der Steege, G
    Bruinenberg, M
    Schaapveld, M
    Niessen, RC
    Berends, MJW
    Sijmons, RH
    Hofstra, RMW
    de Vries, EGE
    Kleibeuker, JH
    [J]. GENES CHROMOSOMES & CANCER, 2005, 43 (04) : 377 - 382
  • [8] Limited relevance of the CHEK2 gene in hereditary breast cancer
    Dufault, MR
    Betz, B
    Wappenschmidt, B
    Hofmann, W
    Bandick, K
    Golla, A
    Pietschmann, A
    Nestle-Krämling, C
    Rhiem, K
    Hüttner, C
    Von Lindern, C
    Dall, P
    Kiechle, M
    Untch, M
    Jonat, W
    Meindl, A
    Scherneck, S
    Niederacher, D
    Schmutzler, RK
    Arnold, N
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (03) : 320 - 325
  • [9] Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251
  • [10] The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
    Falck, J
    Mailand, N
    Syljuåsen, RG
    Bartek, J
    Lukas, J
    [J]. NATURE, 2001, 410 (6830) : 842 - 847